Please use this identifier to cite or link to this item:
|Title:||A Retrospective Study of Topical Lidocaine 5% Plasters in Chronic Off-Label Pain Conditions|
|ANZCA/FPM Author:||Slattery, P|
|Abstract:||Dear Editor, Among many formulations, lidocaine (lignocaine) is available in a transdermal plaster (patch) containing 5% w/w lidocaine (Versatis®, trademark of Grünenthal GmbH used by Seqirus as an authorized user). This formulation is approved for symptomatic treatment of neuropathic pain associated with herpes zoster infection (post-herpetic neuralgia); thus, use of these plasters for other pain conditions is considered off-label. The use of lidocaine 5% plasters (L5%P) in off-label indications has been explored in a limited number of small studies. Currently, L5%P are recommended as a second-line treatment for neuropathic pain in a systematic review by Finnerup et al., limited by weak...|
|Description:||Ethics and governance: This project was approved by the Southern Adelaide Local Health Network Human Research Ethics Committee under reference AUD/19/SAC/76 and site-specific assessment reference AR/19/SAC/76|
|Journal Title:||Pain Medicine|
|Appears in Collections:||Scholarly and Clinical|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.